Article Information

Rectification: This article was remedied for missing Funding/Support, Role of the Sponsors, and Additional Contributions proclamations on December 5, 2017.

Acknowledged for Publication: August 7, 2017.

Comparing Author: Marcel O. Bonn-Miller, PhD, University of Pennsylvania Perelman School of Medicine, 3440 Market St, Ste 370, Philadelphia, PA 19104 (

Creator Contributions: Dr Bonn-Miller had full admittance to the entirety of the information in the investigation and assumes liability for the honesty of the information and the precision of the information examination.

Idea and plan: Bonn-Miller, Loflin, Thomas, Vandrey.

Securing, investigation, or understanding of information: All creators.

Drafting of the composition: Bonn-Miller, Loflin, Marcu, Vandrey.

Basic update of the original copy for significant scholarly substance: Bonn-Miller, Loflin, Thomas, Hyke, Vandrey.

Measurable examination: Loflin, Marcu.

Gotten subsidizing: Bonn-Miller.

Regulatory, specialized, or material help: Bonn-Miller, Loflin, Thomas, Hyke, Vandrey.

Oversight: Bonn-Miller.

Irreconcilable situation Disclosures: All creators have finished and presented the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Bonn-Miller, Thomas, and Vandrey detailed filling in as unpaid board individuals from the Institute for Research on Cannabinoids. Dr Bonn-Miller detailed accepting individual expenses from Zynerba Pharmaceuticals, the Lambert Center for the Study of Medicinal Cannabis and Hemp, the Realm of Caring Foundation, Tilray, CW Botanicals, Insys Therapeutics, International Cannabis and Cannabinoids Institute, the Medical Cannabis Institute, and Aphria. Dr Vandrey revealed accepting individual charges from Zynerba Pharmaceuticals, CW Hemp, Battelle Memorial Institute, and Insys Pharmaceuticals. No different revelations were accounted for.

Subsidizing/Support: This task was financed by an award from the Institute for Research on Cannabinoids (IROC), a 501(c)(3) philanthropic association upheld by singular gifts.

Job of the Funder/Sponsor: Although Drs Bonn-Miller, Thomas, and Vandrey fill in as unpaid board individuals from IROC, the establishment had no influence in the plan or lead of the examination; assortment, the executives, investigation, or understanding of the information; readiness, survey, or endorsement of the composition; or choice to present the original copy for distribution.

Extra Contributions: We thank the Realm of Caring Foundation for their office and staff uphold for the execution of this task. They didn’t get remuneration for their commitment.



Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for clinical use: a methodical audit and meta-examination. JAMA. 2015;313(24):2456-2473.

ArticlePubMedGoogle ScholarCrossref


Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. Cannabinoid portion and name precision in eatable clinical cannabis items. JAMA. 2015;313(24):2491-2493.

ArticlePubMedGoogle ScholarCrossref


US Food and Drug Administration. 2016 Warning letters and test results for cannabidiol-related items. Gotten to August 15, 2017.


Babalonis S, Haney M, Malcolm RJ, et al. Oral cannabidiol doesn’t create a sign for misuse risk in continuous pot smokers. Medication Alcohol Depend. 2017;172:9-13.

Leave a Reply

Your email address will not be published. Required fields are marked *